Physician profile
Garfield Johnson
NPI 1104814573
$9,678.90
in general payments reported to CMS, 2019-2025
22 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 83% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $2,097 · 2021: $748 · 2022: $2,791 · 2023: $1,007 · 2024: $1,068 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,272 · Travel and Lodging: $3.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.99 |
| Travel and Lodging | $3.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $2,265.00 | 2022 | |
| Acclarent, INC | $1,543.19 | 2019-2023 | Acclarent Aera, Trudi Nav Cable, Relieva Spinplus |
| Medtronic USA, INC. | $1,423.40 | 2019-2020 | |
| Integra Lifesciences Corporation | $903.48 | 2024-2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Stryker Corporation | $734.25 | 2019-2022 | |
| Aerin Medical INC. | $444.81 | 2019-2024 | |
| Inspire Medical Systems, INC. | $426.37 | 2023-2025 | Inspire |
| Optinose US, INC. | $398.70 | 2019-2024 | |
| Medtronic, INC. | $313.59 | 2023-2025 | Propel, Sinuva |
| Intersect Ent, INC. | $308.08 | 2019-2021 | |
| Neurent Medical Limited | $258.45 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Glaxosmithkline, LLC. | $213.91 | 2023-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $142.26 | 2023-2024 | Dupixent |
| Genzyme Corporation | $88.42 | 2022-2025 | |
| Boston Scientific Corporation | $56.27 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $33.00 | 2023-2024 | Olympus, Olympus |
| Allergan, INC. | $29.83 | 2019-2020 | |
| Ensodata, INC. | $23.43 | 2025 | |
| Pharming Healthcare, INC. | $20.75 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $20.01 | 2024 | Dupixent |
| Arbor Pharmaceuticals, INC. | $16.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garfield Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.